| American Association of Clinical Endocrinology
History Exam Laboratory Diagnostic procedures Risk calculators Ill. Screening for and Assessing Lipid Disorders and ASCVD Risk Personal: smoking, diet, physical activity, impaired glucose tolerance, metabolic syndrome, diabetes, obesity,
Information
Domain:
Source:
Link to this page:
Documents from same domain
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS …
pro.aace.comduration of diabetes, presence of comorbidities, diabetic complications, and hypoglycemia risk • Fied regimen Increase TDD by 2 U • Adustable regimen • FBG 180 mg/dL add 20 of TDD • FBG 140180 mg/dL add 10 of TDD • TDD 0.30.5 U/gFBG 110139 mg/dL add 1 unit • If hypoglycemia reduce TDD by • BG 0 mg/dL 10 20 • BG 40 mg/dL 20 40
AMERICAN ASSOCIATION OF CLINICAL …
pro.aace.comcrosses medical, social, and economic lines. These guide-lines have been developed by the American Association of Clinical Endocrinologists (AACE) with hopes of reduc-ing the risk of osteoporosis-related fractures and thereby maintaining the quality of life for people with osteopo-rosis. The guidelines use the best evidence, taking into
AACE COMPREHENSIVE TYPE 2 DIABETES 2 0
pro.aace.comTYPE 2 DIABETES MANAGEMENT ALGORITHM 1. Lifestyle modification underlies all therapy (e.g., weight control, physical activity, sleep, etc.) ... Lifestyle Therapy: Physician/RD counseling, web/remote program, structured multidisciplinary program Medical Therapy (BMI 2 27): Surgical Therapy (BMI 2 35): Endoscopic procedures, gastric banding ...
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION …
pro.aace.comachieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 …
Initiating and Intensifying Insulin Therapy in Patients ...
pro.aace.comcontrol and preserve beta-cell function in patients with newly diagnosed T2D and severe, symptomatic hyperglycemia. 1-3 • By treating patients with insulin before diabetes has progressed (typically for 2 weeks to 3 months), glucolipotoxicity is rapidly reversed, and beta -cells are given the chance to “rest.” 1-3
IV Insulin for Hospitalized Patients
pro.aace.comhospitalized patients has led to updates in clinical practice guidelines1 • Several published guidelines address the management of hyperglycemia in hospitalized patients, in both critical and non-critical settings2-7 1. Lansang MC, et al. Cleve Clin J Med. 2016;83(5 Suppl 1):S34-S43. 2. Qaseem A, et al. Am J Med Qual. 2014;29(2):95-98. 3.
Related documents
Secondary Prevention of Cardiovascular Disease (CVD)
www.ahrq.govsignificant atherosclerotic cardiovascular disease including a history of myocardial infarction, a history of angina, a history of prior revascularization – either stenting or bypass surgery, a history of stroke or transient ischemic attack or TIA, and a history of …
Major Recommendations for Statin Therapy for ...
www.mplsheart.comAtherosclerotic Cardiovascular Disease Prevention 2013 ACC/AHA Blood Cholesterol Guideline mplsheart.com S413160 20871 0714 ©2014 ALLINA HEALTH SYSTEM. TM A TRADEMARK OF ALLINA HEALTH SYSTEM. MINNEAPOLIS HEART INSTITUTE® AND MHI ® ARE TRADEMARKS OF MINNEAPOLIS HEART INSTITUTE, INC. Algorithm adapted from …
DEATH CERTIFICATES
www.doj.nh.govCerebrovascular accident due to atherosclerotic cardiovascular disease Coronary artery disease Ischemic heart disease Myocardial infarction (acceptable but it’s preferred if a cause, such as ASCVD, is listed) Renal failure due to diabetes Ruptured abdominal aortic aneurysm
2018 Guideline on the Management of Blood Cholesterol
www.acc.orgA healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In younger individuals, healthy lifestyle can reduce development of risk factors and is the foundation of ASCVD risk reduction. In young adults 20 to
ACC/AHA lipid guidelines: Personalized care to prevent ...
www.ccjm.orgrisk of atherosclerotic cardiovascular disease according to the Pooled Cohort Equations, as well as risk-enhancing factors. Statins are the foundation of pharmacologic therapy, to which ezetimibe and, if necessary, a proprotein con-vertase subtilisin/kexin type 9 inhibitor can be added to achieve lipid goals.
An overview of cardiovascular disease and research
www.rand.orgthrombosis; and other, less common, cardiovascular diseases. 1.1.1 Coronary heart disease Coronary heart disease (CHD), also called coronary artery disease (CAD) and atherosclerotic heart disease, is the end result of the accumulation of atheromatous plaques5 within the walls of the arteries that supply the myocardium (the muscle of the heart).
Atherosclerotic Cardiovascular Disease (ASCVD) Primary ...
wa.kaiserpermanente.orgASCVD, or atherosclerotic cardiovascular disease, is caused by plaque buildup in arterial walls and refers to the following conditions: • Coronary heart disease (CHD), such as myocardial infarction, angina, and coronary artery stenosis > 50%.